Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.72 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.72 |
| ▸ | PIM1 | P11309 | 2/20 | 0.68 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.53 |
| ▸ | FYN | P06241 | 10/20 | 0.50 |
| ▸ | ABL1 | P00519 | 2/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.49 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.49 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.49 |
| ▸ | PGK1 | P00558 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.49 |
| ▸ | GSK3A | P49840 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | CDK9 | P50750 | 1/20 | 0.49 |
| ▸ | JAK3 | P52333 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2943040 | 0.87 | PIK3CD (0.70) | PIK3CDPIK3R1PIM1MKNK1FYN | |
| SCHEMBL13234328 | 0.86 | MKNK1 (0.61) | PIK3CDPIK3R1PIM1MKNK1FYN | |
| SCHEMBL2943291 | 0.86 | FYN (0.69) | PIK3CDPIK3R1PIM1MKNK1FYN | |
| SCHEMBL2942575 | 0.85 | PIM1 (0.66) | PIK3CDPIK3R1PIM1MKNK1FYN | |
| SCHEMBL2951018 | 0.85 | MKNK1 (0.67) | PIK3CDPIK3R1PIM1MKNK1FYN | |
| SCHEMBL2945203 | 0.84 | PIM1 (0.71) | PIK3CDPIK3R1PIM1MKNK1FYN | |
| SCHEMBL2949545 | 0.84 | NTRK1 (0.68) | PIK3CDPIK3R1PIM1MKNK1FYN | |
| SCHEMBL13234372 | 0.84 | PIM1 (0.74) | PIK3CDPIK3R1PIM1MKNK1FYN | |
| SCHEMBL2944865 | 0.84 | FYN (0.69) | PIK3CDPIK3R1PIM1MKNK1FYN | |
| SCHEMBL2949374 | 0.84 | MKNK1 (0.77) | PIK3CDPIK3R1PIM1MKNK1FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458463-B2 | Method for treatment of diabetes by a small molecule inhibitor for GRK5 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-10-04 | — | — | US | claimed |
| EP-2818471-A1 | Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-12-31 | — | — | EP | claimed |
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | BIOGEN IDEC MA INC. (US) | 2011-01-27 | — | — | US | claimed |
| US-9458463-B2 | Method for treatment of diabetes by a small molecule inhibitor for GRK5 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-10-04 | — | — | US | disclosed |
| US-20150079108-A1 | KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-03-19 | — | — | US | disclosed |
| EP-2818471-A1 | Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-12-31 | — | — | EP | disclosed |
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | BIOGEN IDEC MA INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150079108-A1 | KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY | GCKR, GRK4, GRK5 | PIK3CD 567/4885PIK3R1 780/4885PIM1 796/4885 |
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | IRAK1, IRAK2, IRAK3 | PIK3CD 505/4885PIK3R1 352/4885PIM1 147/4885 |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | MAP4K2, MAP3K1, MAP3K2 | PIK3CD 101/4885PIK3R1 410/4885PIM1 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.